Brief: Microbix Biosystems To Provide A Global External Quality Assessment Program To Support Clinically-Effective Covid-19 Testing
09/04/2020 13:01
April 9 (Reuters) - Microbix Biosystems Inc MBX.TO :
* MICROBIX BIOSYSTEMS INC - TO PROVIDE A GLOBAL EXTERNAL
QUALITY
ASSESSMENT PROGRAM TO SUPPORT CLINICALLY-EFFECTIVE COVID-19
TESTING
Source text for Eikon: ID:nGNX2K5cWb
Further company coverage: MBX.TO
(Reuters.Briefs@thomsonreuters.com)
Recent news on Microbix Biosystems
See all newsCanada's Microbix Q3 revenue rises on higher antigen, QAPs sales
Brief: Microbix Biosystems Q3 Revenue CAD 4.1 Million
Canada's Microbix Biosystems Q2 revenue falls 37% on weaker China sales
Canada's Microbix Q1 revenue down 30% on China sales decline
Brief: Microbix Biosystems Q1 Revenue CAD 4.2 Million